Author:
Labora Amanda,Shimizu Takayuki,Moore Alexandra,Premji Alykhan,Armstrong Wesley R.,Chen Kevin Y.,Link Jason,Chan Charlotte S.,Allen-Auerbach Martin S.,Donahue Timothy R.
Funder
Japanese Society of Hepato-Biliary-Pancreatic Surgery
Dokkyo Medical University for Overseas Challenge Program
Jonsson Cancer Center Foundation
H&H Lee Surgical Research Scholars Program
National Cancer Institute
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42. https://doi.org/10.1001/jamaoncol.2017.0589.
2. Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA: Cancer J Clin. 2018;68(6):471–87. https://doi.org/10.3322/caac.21493.
3. Babazadeh NT, Schlund DJ, Cornelius T, et al. Should 68Ga-DOTATATE PET/CT be performed routinely in patients with neuroendocrine tumors before surgical resection? World J Surg. 2020;44(2):604–11. https://doi.org/10.1007/s00268-019-05216-3.
4. Cai W, Tan Y, Ge W, Ding K, Hu H. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study. Cancer Med. 2018;7(6):2699–709. https://doi.org/10.1002/cam4.1507.
5. The Impact of 68Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom. J Nucl Med. Accessed April 17, 2023. https://jnm.snmjournals.org/content/57/1/34.long